Prior to founding Hanne Capital in early 2017, Mr. Zhou was IC member and partner in charge of healthcare investments at New Horizon Capital for 9 years. Under his leadership the team has made investments across all segments of healthcare industry including a number of landmark deals. His representative portfolios include Hile Bio-tech (SH: 603718)，HEC Changjiang Pharma (HK:1558)，Golden Meditech (HK: 801) , HybriBio (SZ: 300639) and Ready Health (SH: 600090)，SinoMed, Heal Force Bio-meditech ZaiLab, OrbiePharm and Allgens. Mr. Zhou was a founding of Qiming Ventures before joining New Horizon in 2008. Early in his investment career Mr. Zhou was a strategic investment director at Cisco Systems where he was responsible for strategic investments, M&A as well as strategic partnership in Asia Pacific region. Mr. Zhou has over 13 years of investment experience with the last 8 years focusing on healthcare industry.
Mr. Zhou holds an MBA degree from Kellogg School of Management, Northwestern University as well as bachelor and master degrees both from Shanghai Jiao Tong University.
About Hanne Capital
Founded in 2017, Hanne Capital is a healthcare specialty private equity investment fund focusing on growth opportunities in Greater China. The founding partners are all veterans with years of senior leadership experience at industry leading private equity fund or world-renowned multinationals in pharma, medtech & biotech industries. Each founding partner has achieved industry milestones in their previous career. Hanne team consists of seasoned professionals with sharp business acumen and rich experience of investments and believes strongly in high standards of ethics and professionalism.
Historically the founding partners have deployed over US$330 million into a number of companies and played pivotal roles in the growth of these investees. Many of our portfolios have successfully listed on renowned stock exchanges in mainland China, US, Hong Kong and Taiwan with a collective market capitalization over US$6.2 billion.
We look for companies with great growth potential in pharma & biotech, medtech and healthcare services sectors and choose to work with management teams with integrity and solid execution capabilities. We will work closely with our portfolios as an extended team to create value by leveraging our broad network of connections and deep domain expertise in growth strategy, business developments, cross-border IP transactions and operation improvements.